AvaGen is the new genetic test from Avellino that identifies risk for developing keratoconus and the
presence of corneal dystrophies. AvaGen will be available in the U.S. late 2019/early 2020.
A preemptive diagnostic tool, AvaGen gives physicians and patients the advantage of earlier detection
to help make informed choices for healthier eye and vision care.
The ability of genetic tests such as AvaGen to detect potentially pathogenic or deleterious variants
before symptoms appear can assist eyecare professionals in recommending prevention management
techniques, treatments, and refractive surgery options.
Physicians can work hand-in-hand with patients to implement healthy eyecare practices years or even
decades earlier than before, potentially delaying the onset or progression of eye-related diseases.
While some genetic eye diseases such as keratoconus cannot be prevented, early intervention may help
slow the onset or progression of the disease. Early intervention could potentially change outcomes in
the long term, making a significant impact on quality of life for some patients.
See early prevention and improved
The AAO genetic task force states:
Avellino offers a genetic counselor network at no cost to help support physicians and their patients who
receive at-risk or positive test results. Genetic counselors provide further explanation of what the test
results may mean for patients and how they might affect the family. This added support may help with the
creation of a plan of action for moving forward.
For more information on the genetic counselor network, contact Avellino.
1. American Academy of Ophthalmology. Recommendations for Genetic Testing for Inherited Eye Diseases, 2014.
Accessed August 12, 2019.